SCHEMBL6282764

SCHEMBL6282764

O=C(Nc1ncc(-c2ccccc2)s1)Nc1ccccc1O

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 1/20 0.63
KDR P35968 6/20 0.62
GSTO1 P78417 1/20 0.58
CCNE1 P24864 2/20 0.56
CDK2 P24941 2/20 0.56
CDK5 Q00535 2/20 0.56
SCD O00767 1/20 0.56
ACP1 P24666 1/20 0.54
RET P07949 1/20 0.53
FLT1 P17948 1/20 0.53
MAPK14 Q16539 1/20 0.53
MKNK1 Q9BUB5 1/20 0.50
FFAR2 O15552 1/20 0.50
NPC1 O15118 2/20 0.48
RAB9A P51151 2/20 0.48
UCHL1 P09936 1/20 0.46
MEN1 O00255 2/20 0.46
GAA P10253 2/20 0.46
KMT2A Q03164 2/20 0.46
CNR2 P34972 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6278417 0.85 CNR1 (0.69) CNR1KDRGSTO1CCNE1CDK2
SCHEMBL6281775 0.83 CNR1 (0.82) CNR1KDRGSTO1CCNE1CDK2
SCHEMBL6288100 0.82 SMN1; SMN2 (0.59) CNR1KDRGSTO1CCNE1CDK2
SCHEMBL6285499 0.81 CNR1 (0.79) CNR1KDRGSTO1CCNE1CDK2
SCHEMBL6282665 0.81 CCNE1 (0.53) KDRCCNE1CDK2CDK5RET
SCHEMBL6281756 0.80 CDK2 (0.70) CNR1KDRCCNE1CDK2CDK5
SCHEMBL6279016 0.79 CNR1 (0.67) CNR1KDRGSTO1CCNE1CDK2
SCHEMBL6282391 0.78 CNR1 (0.74) CNR1KDRGSTO1CCNE1CDK2
SCHEMBL6279008 0.78 KDR (0.66) CNR1KDRGSTO1CCNE1CDK2
SCHEMBL6288008 0.77 CCNE1 (0.63) KDRCCNE1CDK2CDK5RET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040157827-A1 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents PEVARELLO PAOLO (IT) 2004-08-12 US claimed
US-20030187040-A1 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents PHARMACIA & UPJOHN SPA (IT) 2003-10-02 US claimed
US-6863647-B2 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents PHARMACIA & UPJOHN S.P.A. (IT) 2005-03-08 US disclosed
US-20040157827-A1 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents PEVARELLO PAOLO (IT) 2004-08-12 US disclosed
US-20030187040-A1 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents PHARMACIA & UPJOHN SPA (IT) 2003-10-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030187040-A1 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents UCK2, ULK3, CDK2 CNR1 1317/4885KDR 622/4885GSTO1 3939/4885
US-20040157827-A1 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents UCK2, ULK3, CDK2 CNR1 1317/4885KDR 622/4885GSTO1 3939/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.